Stock fact sheet · data as of
Viatris Inc. (VTRS): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative / Distressed
Is VTRS undervalued?
At 17.44 (close of 16 Oct 2026), VTRS trades within a few percent of the GLS average fair value of 18.82 (7.3% below fair value). 3 models produced a value and they split 2 above the price to 1 below. A stock priced at fair value earns about half of the Wheel Score's Value points; the rest of the score comes from health, moat, premium and stability.
The average is built from just 3 models (DCF, 10 Cap, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files VTRS under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for VTRS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 19.14 | +10% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 30.24 | +73% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 7.06 | -60% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -11.55 | -166% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 22.17 | +27% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Viatris Inc. scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 1.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -12.0%, ROE -23.9%, ROA -9.5% - with debt at 1.00 times equity and a free-cash-flow yield of 9.4%.
The dividend yield is 2.75% at a payout ratio of -136%; for a wheel trader holding assigned shares the dividend adds to the covered-call premium, and the ex-dividend date is worth knowing before a call is sold. Revenue comes mainly from Brands 65%, Generics 35% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | -12.0% |
|---|---|---|---|
| GLS Moat | 1.5 / 10 | ROE | -23.9% |
| Debt / equity | 1.00 | ROA | -9.5% |
| Free-cash-flow yield | 9.4% | Payout ratio | -136% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 45: Weak
With a Wheel Score of 45 Viatris Inc. sits in the Weak band, capped at 45 because the engine files it as Speculative / Distressed. The parts - Value 16/25, Health 16/20, Moat 2/15, Premium 20/20, Stability 20/20 - show where: Moat (2/15) scores lowest.
Implied volatility is 39% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. The option chain is deep: 124,166 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 8.7M shares a day on a market cap of $20.0B, with a beta of 0.86; the Stability part of the Wheel Score gives that 20 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 16 / 25 | 7% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 2 / 15 | moat 1.5/10 | |
| Premium | 20 / 20 | implied volatility 39% | |
| Stability | 20 / 20 | 8.7M shares/day, $20.0B cap, beta 0.86 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026 (before the open), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Viatris Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ZTS Zoetis Inc. | 75.34 | 95.52 | +21% | 89Prime | $31.6B |
| ELAN Elanco Animal Health Incorporated | 23.54 | 11.45 | -106% | 45Weak | $11.8B |
| RDY Dr. Reddy's Laboratories Limited | 12.75 | 153.50 | +92% | 82Prime | $10.6B |
| HLN Haleon plc | 9.94 | 6.22 | -60% | 69Good | $43.7B |
| TEVA Teva Pharmaceutical Industries Limited | 40.72 | 21.81 | -87% | 59Fair | $47.5B |
| ALKS Alkermes plc | 40.10 | 22.14 | -81% | 56Fair | $6.7B |
| TAK Takeda Pharmaceutical Company Limited | 19.01 | 1,108.41 | +98% | 82Prime | $60.3B |
| LNTH Lantheus Holdings, Inc. | 99.99 | 183.99 | +46% | 60Fair | $6.5B |
| AMRX Amneal Pharmaceuticals, Inc. | 19.25 | 12.43 | -55% | 57Fair | $6.1B |
| INDV Indivior Pharmaceuticals Inc | 33.62 | 56.88 | +41% | 75Good | $4.2B |
| RGC Regencell Bioscience Holdings Limited | 8.11 | 0.0281 | -28765% | 25Weak | $4.0B |
| HCM HUTCHMED (China) Limited | 13.94 | 2.93 | -376% | 42Weak | $2.4B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about VTRS
Is VTRS undervalued right now?
Not meaningfully: at 17.44 the stock trades within a few percent of the GLS average fair value of 18.82 (7.3% below fair value, data as of 16 Oct 2026).
What is the Wheel Score of VTRS and what does it mean?
VTRS scores 45 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for VTRS?
18.82 per share as of 16 Oct 2026 - the simple average of the 3 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Viatris Inc. report earnings next?
The next earnings report is due on 5 Nov 2026 (before the open), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does VTRS have listed options, and how liquid are they?
Yes. The nightly snapshot found 226 listed contracts with 124,166 open interest across all expiries and implied volatility of 39% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.